<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959500</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-Ⅱ-01</org_study_id>
    <nct_id>NCT04959500</nct_id>
  </id_info>
  <brief_title>Newly Diagnosed Glioblastoma</brief_title>
  <official_title>Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma: A Randomized Double-blind Multicenter Prospective Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for&#xD;
      Newly Diagnosed Glioblastoma.Take PFS as the main evaluation index, the purpose is to&#xD;
      evaluate its effectiveness&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) assessed by IRC</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>PFS was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The progression free survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>PFS was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>OS was defined as the time from the date of study enrollment to the date of death due to any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Radiation therapy, Temozolomide and anlotinib Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Anlotinib hydrochloride will be given with a daily dose of 10 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Experimental: Radiation therapy, Temozolomide and Placebo Patients will receive standard radiation therapy plus temozolomide (Stupp regimen). Placebo will be given with a daily dose of 0 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride</intervention_name>
    <description>Drug: Anlotinib Hydrochloride Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0 Gy given 5 days a week for a total of 54-60 Gy.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understood and Signed an informed consent form., with good compliance&#xD;
&#xD;
          -  Age: 18-75 years old；.Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 to 2；Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Glioblastoma confirmed by histology ;&#xD;
&#xD;
          -  Random time is 4-6 weeks from the last operation , and the investigator judges that&#xD;
             the surgical wound has healed well;&#xD;
&#xD;
          -  Within 5 days before administration, the dosage of corticosteroids was stable or&#xD;
             gradually decreased;&#xD;
&#xD;
          -  Male or female subjects should agree to use an adequate method of contraception&#xD;
             starting with the first dose of study therapy through 6 months after the last dose of&#xD;
             study ；Not Pregnant or breastfeeding women,Pregnancy before pregnancy screening, the&#xD;
             women who blood / urine results were positivetherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have previously received systemic radiotherapy and chemotherapy for GBM;&#xD;
&#xD;
          -  IDH1/2 mutations are present&#xD;
&#xD;
          -  Contraindicated for MRI examination&#xD;
&#xD;
          -  The tumor only occurs in the brain stem&#xD;
&#xD;
          -  Radiologically obvious diffuse meningeal dissemination&#xD;
&#xD;
          -  Imaging shows that the tumor has invaded the periphery of important blood vessels or&#xD;
             the investigator judges that the tumor is very likely to invade important blood&#xD;
             vessels and cause fatal hemorrhage, cerebrovascular malformations or other bleeding&#xD;
             tendency during the subsequent study period;&#xD;
&#xD;
          -  Patients with arterial or venous thromboembolic events occurred within 6 months, such&#xD;
             as cerebrovascular accident , deep vein thrombosis and pulmonary embolism；&#xD;
&#xD;
          -  Other malignant tumors have occurred or are currently present at the same time within&#xD;
             3 years.&#xD;
&#xD;
          -  There are many factors that affect oral medications ;&#xD;
&#xD;
          -  Received anti-tumor Chinese patent medicine which were approved by NMPA Within 2 weeks&#xD;
             before the start of the study.&#xD;
&#xD;
          -  A clear history of neurological or psychiatric diseases, moderate or higher epilepsy ,&#xD;
             moderate or higher aphasia or dementia&#xD;
&#xD;
          -  Participated in other anti-tumor drug clinical trials within 4 weeks before grouping;&#xD;
&#xD;
          -  Other conditions which are not fit for this study assessed by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongping Chen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongping Chen, Doctor</last_name>
    <phone>13500002457</phone>
    <email>chenzhp@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuanyuan Chen, Doctor</last_name>
    <phone>13738103808</phone>
    <email>chenyy@zjcc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao Jiang, Master</last_name>
      <phone>13500568891</phone>
      <email>jianghao1223@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing TianTan Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing Province</state>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Song Lin, Doctor</last_name>
      <phone>1380112769</phone>
      <email>linsong2005@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth Madical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Zheng, Doctor</last_name>
      <phone>18600317539</phone>
      <email>navyzw@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The General Hospital of the People's Liberation Army (PLAGH)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Longsheng Pan, Doctor</last_name>
      <phone>1390136562</phone>
      <email>panls301@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Shiyu Feng, Undergraduate</last_name>
      <phone>15011288969</phone>
      <email>fsy72123@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing Province</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Run Cai, Doctor</last_name>
      <phone>13072341313</phone>
      <email>cairun0519@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junxin Wu, Doctor</last_name>
      <phone>13635293859</phone>
      <email>junxinwu@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pengfei Sun, Doctor</last_name>
      <phone>13919485464</phone>
      <email>sunpengfeiby@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juntao Ran, Doctor</last_name>
      <phone>13893399585</phone>
      <email>ranjt@lzu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongping Chen, Doctor</last_name>
      <phone>13500002457</phone>
      <email>chenzhp@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yuanyuan Chen, Doctor</last_name>
      <phone>13738103808</phone>
      <email>chenyy@zjcc.org.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianming Li, Doctor</last_name>
      <phone>13502869369</phone>
      <email>lxm1828@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital Sun Yat-sen University</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <zip>519000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhigang Liu, Doctor</last_name>
      <phone>18627585860</phone>
      <email>Zhigangliu1983@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The affiliated hospital of xuzhou medical university</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guihong Liu, Master</last_name>
      <phone>18052268720</phone>
      <email>2995181541@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of NanChang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meihua Li, Doctor</last_name>
      <phone>13970052318</phone>
      <email>Limeihua2000@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yiqiang Tang, Master</last_name>
      <phone>13607916372</phone>
      <email>Johnytangyq@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial Hospital</name>
      <address>
        <city>Gansu</city>
        <state>Lanzhou Province</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongyi Cai, Master</last_name>
      <phone>13309492018</phone>
      <email>gschy333@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haozhe Pu, Doctor</last_name>
      <phone>13940070166</phone>
      <email>pzpy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University shabghai cancer center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xueguan Lu, Doctor</last_name>
      <phone>18121199382</phone>
      <email>luxueguan@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of PLA Air Force Medical University</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liang Wang, Doctor</last_name>
      <phone>13319232049</phone>
      <email>Doctorwangliang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanhui Liu, Doctor</last_name>
      <phone>18980601509</phone>
      <email>827005432@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuejun Yang, Doctor</last_name>
      <phone>13011329950</phone>
      <email>ydenny@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yonghong Hua, Doctor</last_name>
      <phone>13858032047</phone>
      <email>yonghonghua@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhongping Chen</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

